Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system

Journal of Clinical Investigation

Volumn 116, Issue 6, 2006, Pages 1731-1737

  Mergia, Evanthia ^a   Friebe, Andreas ^a   Dangel, Oliver ^a   Russwurm, Michael ^a   Koesling, Doris ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE RECEPTOR; HETERODIMER; ISOENZYME; NITRIC OXIDE; NITRIC OXIDE RECEPTOR; NITRIC OXIDE SYNTHASE; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; IN VIVO STUDY; INTRACELLULAR SPACE; MENTAL INSTABILITY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ANIMALS; AORTA; BLOOD PRESSURE; BRAIN; CYCLIC GMP; GENE TARGETING; GUANYLATE CYCLASE; ISOENZYMES; LUNG; MICE; MICE, KNOCKOUT; NITRIC OXIDE; PROTEIN SUBUNITS; RECEPTORS, GUANYLATE CYCLASE-COUPLED; SIGNAL TRANSDUCTION; VASODILATION;

EID: 33745217855     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27657     Document Type: Article

References (30)

1. Waldman, S.A., and Murad, F. 1987. Cyclic GMP synthesis and function. Pharmacol. Rev. 39:163-196.
2. Moncada, S., and Higgs, E.A. 1995. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1319-1330.
3. Ignarro, L.J. 2002. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53:503-514.
4. Feil, R., Lohmann, S.M., de Jonge, H., Walter, U., and Hofmann, F. 2003. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 93:907-916.
5. Munzel, T., et al. 2003. Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase. Circulation. 108:2172-2183.
6. Kuhn, M. 2003. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 93:700-709.
7. Rybalkin, S.D., Yan, C., Bornfeldt, K.E., and Beavo, J.A. 2003. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93:280-291.
8. Friebe, A., and Koesling, D. 2003. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. 93:96-105.
9. Russwurm, M., and Koesling, D. 2002. Isoforms of NO-sensitive guanylyl cyclase. Mol. Cell. Biochem. 230:159-164.
10. 1 guanylyl cyclase to synaptic membranes. J. Biol. Chem. 276:44647-44652.
11. Garthwaite, J., et al. 1995. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48:184-188.
12. Pfeifer, A., et al. 1998. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 17:3045-3051.
13. Geiselhöringer, A., et al. 2004. IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. EMBO J. 23:4222-4231.
14. Moncada, S., Radomski, M.W., and Palmer, R.M. 1988. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem. Pharmacol. 37:2495-2501.
15. Waldmann, R., and Walter, U. 1989. Cyclic nucleotide elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade. Eur. J. Pharmacol. 159:317-320.
16. Vallance, P., Collier, J., and Moncada, S. 1989. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:997-1000.
17. Van Vliet, B.N., Chafe, L.L., and Montani, J.P. 2003. Characteristics of 24 h telemetered blood pressure in eNOS-knockout and C57Bl/6J control mice. J. Physiol. 549:313-325.
18. Hussain, M.B., Hobbs, A.J., and MacAllister, R.J. 1999. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta. Br. J. Pharmacol. 128:1082-1088.
19. Brandes, R.P., et al. 2000. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase. Hypertension. 35:231-236.
20. Karim, S.M., et al. 2004. Vascular reactivity in heart failure: role of myosin light chain phosphatase. Circ. Res. 95:612-618.
21. Champion, H.C., Bivalacqua, T.J., Takimoto, E., Kass, D.A., and Burnett, A.L. 2005. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc. Natl. Acad. Sci. U. S. A. 102:1661-1666.
22. Kim, D., et al. 2001. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 104:2338-2343.
23. Münzel, T., Daiber, A., Ullrich, V., and Mülsch, A. 2005. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol. 25:1551-1557.
24. Friebe, A., Schultz, G., and Koesling, D. 1996. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 15:6863-6868.
25. Stasch, J.P., et al. 2001. NO-independent regulatory site on soluble guanylate cyclase. Nature. 410:212-215.
26. Gainetdinov, R.R., et al. 2003. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 38:291-303.
27. Lakso, M., et al. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. U. S. A. 93:5860-5865.
28. 1 isoform of NO-sensitive guanylyl cyclase in brain. Cell. Signal. 15:189-195.
29. Russwurm, M., and Koesling, D. 2005. Purification and characterization of NO-sensitive guanylyl cyclase. Methods Enzymol. 396:492-501.
30. Brooker, G., Harper, J.F., Terasaki, W.L., and Moylan, R.D. 1979. Radioimmunoassay of cyclic AMP and cyclic GMP. Adv. Cyclic Nucleotide Res. 10:1-33.